Historical Valuation
GeneDx Holdings Corp (WGS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7.57 is considered Overvalued compared with the five-year average of 31.51. The fair price of GeneDx Holdings Corp (WGS) is between 100.88 to 135.86 according to relative valuation methord. Compared to the current price of 136.63 USD , GeneDx Holdings Corp is Overvalued By 0.57%.
Relative Value
Fair Zone
100.88-135.86
Current Price：136.63
0.57%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
GeneDx Holdings Corp (WGS) has a current Price-to-Book (P/B) ratio of 13.08. Compared to its 3-year average P/B ratio of 5.33 , the current P/B ratio is approximately 145.56% higher. Relative to its 5-year average P/B ratio of 3.64, the current P/B ratio is about 259.50% higher. GeneDx Holdings Corp (WGS) has a Forward Free Cash Flow (FCF) yield of approximately 0.40%. Compared to its 3-year average FCF yield of -91.08%, the current FCF yield is approximately -100.44% lower. Relative to its 5-year average FCF yield of -71.04% , the current FCF yield is about -100.57% lower.
P/B
Median3y
5.33
Median5y
3.64
FCF Yield
Median3y
-91.08
Median5y
-71.04
Competitors Valuation Multiple
AI Analysis for WGS
The average P/S ratio for WGS competitors is 4.11, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS.O) exhibits a P/S ratio of 7.57, which is 84.3% above the industry average. Given its robust revenue growth of 51.86%, this premium appears sustainable.
Performance Decomposition
AI Analysis for WGS
1Y
3Y
5Y
Market capitalization of WGS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of WGS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is WGS currently overvalued or undervalued?
GeneDx Holdings Corp (WGS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7.57 is considered Overvalued compared with the five-year average of 31.51. The fair price of GeneDx Holdings Corp (WGS) is between 100.88 to 135.86 according to relative valuation methord. Compared to the current price of 136.63 USD , GeneDx Holdings Corp is Overvalued By 0.57% .
What is GeneDx Holdings Corp (WGS) fair value?
WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of GeneDx Holdings Corp (WGS) is between 100.88 to 135.86 according to relative valuation methord.
How does WGS's valuation metrics compare to the industry average?
The average P/S ratio for WGS's competitors is 4.11, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS) exhibits a P/S ratio of 7.57, which is 84.30% above the industry average. Given its robust revenue growth of 51.86%, this premium appears sustainable.
What is the current P/B ratio for GeneDx Holdings Corp (WGS) as of Jan 09 2026?
As of Jan 09 2026, GeneDx Holdings Corp (WGS) has a P/B ratio of 13.08. This indicates that the market values WGS at 13.08 times its book value.
What is the current FCF Yield for GeneDx Holdings Corp (WGS) as of Jan 09 2026?
As of Jan 09 2026, GeneDx Holdings Corp (WGS) has a FCF Yield of 0.40%. This means that for every dollar of GeneDx Holdings Corp’s market capitalization, the company generates 0.40 cents in free cash flow.
What is the current Forward P/E ratio for GeneDx Holdings Corp (WGS) as of Jan 09 2026?
As of Jan 09 2026, GeneDx Holdings Corp (WGS) has a Forward P/E ratio of 445.30. This means the market is willing to pay $445.30 for every dollar of GeneDx Holdings Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for GeneDx Holdings Corp (WGS) as of Jan 09 2026?
As of Jan 09 2026, GeneDx Holdings Corp (WGS) has a Forward P/S ratio of 7.57. This means the market is valuing WGS at $7.57 for every dollar of expected revenue over the next 12 months.